Royal Medical Center Review
Tirzepatide GLP-1 weight-loss telehealth · Independently scored 5.7/10
Best for: bloodwork inside the $650/month rather than billed on top
Royal Medical Center falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
Not stated
Lab work
In the price
Coaching
Not stated
No insurance needed · Vetted by our editors
Compounded tirzepatide is priced along four dose tiers, $450 through $1,100/mo, each covering drug, supplies, labs and consultations. Semaglutide is not offered at all. Dr. Dagoberto Rodriguez, M.D. founded the practice, which works nationally by telehealth and treats hormone therapy as its core; the credentialing and the itemization are both unusual for this segment. No pharmacy partner is identified.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Royal Medical Center
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Royal Medical Center at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Tirzepatide
- Starting price
- $450/mo
- What's included
- Medication · Consult · Labs
- FDA status
- No FDA warning letter on record
How Royal Medical Center scores
Six columns, each one computed from something Royal Medical Center has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
0.0/10$650/month is 143% above the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10On the seller's own pages, a price is published before the questionnaire starts; baseline bloodwork is required before a prescription.
Trust & Safety15%
5.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is low.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, labs.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Royal Medical Center
Last checked June 2026- Re-read the price on file across 4 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: low.
What signing up with Royal Medical Center involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Royal Medical Center publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake requires baseline bloodwork, which is more than most of the register asks and slower to complete.
- 3Royal Medical Center does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, labs.
- Cheapest standing monthly prices on record: tirzepatide $650. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether Royal Medical Center serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Royal Medical Center support, as documented
- Phone
- 1-800-625-3837
- info@rmmcenter.com
GLP-1 medications Royal Medical Center offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off Royal Medical Center's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, labs
- No FDA warning letter matched this operator when we searched our enforcement register
- Baseline bloodwork is required before a prescription
Against it
- Tirzepatide at $650 a month, 143% above the $267 register median for the same drug and form
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its tirzepatide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Royal Medical Center charges
Royal Medical Center charges $450/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- tirzepatide — $450/month
- tirzepatide — $650/month
- tirzepatide — $800/month
- tirzepatide — $1100/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Direct Meds dispenses tirzepatide from $249/month, which makes it the honest comparison to run before committing here.
What Royal Medical Center dispenses
Royal Medical Center prescribes tirzepatide (approved as Zepbound and Mounjaro). Between them these are one of the most heavily studied molecules in this class.
What we could verify
Royal Medical Center publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
Our read
Royal Medical Center costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less.
The Bottom Line
Royal Medical Center falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Royal Medical Center
Starting at $450/month. Check today's price, then book the free consultation.
Where Royal Medical Center is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Royal Medical Center review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 7.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See Royal Medical Center's current pricing
Plans start at $450/month. The free consultation is where you learn whether you qualify, and what it costs today.